Rabindra Tirouvanziam obtained an engineering degree from Agro Paris-Tech, a masters in lung physiology from Université Paris XII and a Ph.D. in development biology also from Agro Paris-Tech, for his work on human xenografts in SCID mice conducted at the Institut d’Embryologie du CNRS et College de France in Nogent-sur-Marne.

He then pursued postdoctoral studies in physiology, genetics, immunology and psychiatry at Stanford University, developing a decade-long translational program focused on collection and deep analysis of patient samples and culminating in phase 2 clinical trials in cystic fibrosis and autism spectrum disorder.

Tirouvanziam moved to Atlanta in 2011, where his translational research group of 10+ members focuses on engineering of the human innate immune system and immunometabolic disease. Main diseases of interest affecting the lung (such as cystic fibrosis, bronchiectasis, COVID-19, and tuberculosis), and other organ systems (diabetes, cold tumors, malaria).